[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100618688":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":11,"locations":20,"responsibleParty":32,"collaborators":11,"id":34,"slug":35,"hasResults":36,"nctId":37,"briefTitle":38,"officialTitle":39,"acronym":40,"eligibilityCriteria":41,"healthyVolunteers":36,"sex":42,"minAge":43,"maxAge":11,"enrollmentInfo":44,"targetDuration":11,"studyType":47,"phases":48,"briefSummary":50,"conditions":51,"keywords":53,"overallStatus":55,"whyStopped":11,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":65},{"fullName":5,"class":6},"Nanfang Hospital, Southern Medical University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Standard of care for ARDS+Inhaled Nitric Oxide","EXPERIMENTAL",null,[13],"Procedure: Inhaled Nitric Oxide Therapy",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"PROCEDURE","Inhaled Nitric Oxide Therapy","Patients randomized to the intervention group will receive inhaled nitric oxide (iNO) delivered via the portable INOwill N200 system in addition to standard ARDS care. iNO administration will commence immediately upon enrollment, with its concentration set and titrated in accordance with established clinical practice guidelines.",[9],[21],{"facility":5,"status":11,"city":22,"state":23,"zip":11,"country":24,"countryCode":25,"cosmosGeoPoint":26,"geoPoint":31,"contacts":11},"Guangzhou","Guangdong","China","CN",{"type":27,"coordinates":28},"Point",[29,30],113.25,23.11667,{"lat":30,"lon":29},{"type":33,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100618688","effect-of-inhaled-nitric-oxide-therapy-in-adults-with-moderate-to-severe-acute-respiratory-distress-syndrome-100618688",false,"NCT07334873","Effect of Inhaled Nitric Oxide Therapy in Adults With Moderate-to-Severe Acute Respiratory Distress Syndrome","Evaluation of the Efficacy of Inhaled Nitric Oxide Therapy in Patients With Moderate to Severe Acute Respiratory Distress Syndrome: A Multicenter, Prospective, Randomized Controlled Clinical Trial (ENARCT-ARDS)","ENARCT-ARDS","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Patients diagnosed with moderate-to-severe ARDS according to the 2023 Global (or international) criteria.\n\nExclusion Criteria:\n\n* Known allergy to iNO.\n* Congenital methemoglobinemia.\n* End-stage chronic lung disease (e.g., lung cancer, prior pneumonectomy\u002Flung transplant).\n* Shock (norepinephrine \\>0.5 μg\u002Fkg\u002Fmin or equivalent for \\>6 hours) at treatment initiation.\n* Pulmonary hypertension (PASP \\>45 mmHg by echo or mPAP ≥25 mmHg by catheterization).\n* Serum creatinine \\>2.5 mg\u002FdL (221 μmol\u002FL).\n* Major bleeding (e.g., intracranial, pulmonary) or platelet count \\\u003C20×10⁹\u002FL.\n* Expected ICU\u002Fmechanical ventilation \\\u003C24 hours.\n* Pre-enrollment ECMO therapy.\n* Any investigator-assessed unsuitability for the study.","ALL","18 Years",{"count":45,"type":46},536,"ESTIMATED","INTERVENTIONAL",[49],"NA","The goal of this clinical trial is to evaluate whether inhaled nitric oxide (iNO), added to standard care, can reduce mortality in adults with moderate-to-severe Acute Respiratory Distress Syndrome (ARDS). The main questions it aims to answer are:\n\nDoes iNO therapy reduce 28-day all-cause mortality compared to standard care alone? Does iNO therapy increase the number of ventilator-free days through day 28? If there is a comparison group: Researchers will compare the group receiving iNO plus standard care with the group receiving placebo plus standard care to see if iNO improves survival and other clinical outcomes.\n\nParticipants will:\n\nBe randomly assigned to receive either iNO or a placebo through the ventilator.\n\nReceive all other standard treatments for ARDS as per current guidelines. Be closely monitored for 28 days to track survival, time on the ventilator, and safety.",[52],"ARDS (Moderate or Severe)",[17,54],"ARDS","NOT_YET_RECRUITING","2026-01-11",{"date":58,"type":59},"2026-01-13","ACTUAL",{"date":61,"type":46},"2026-01",{"date":63,"type":46},"2027-12",{"name":5,"class":6},1]